A Multisite Trial of ACQUIREc Therapy

University of Alabama at Birmingham18 enrolled

Overview

A multisite trial to testing different dosage levels of a systematic form of Pediatric Constraint-Induced (CI) Therapy called ACQUIREc Therapy. The high dosage treatment involved 6 hours of daily therapy services for 21 days. This was compared to a moderate dosage level of 3 hours of daily therapy services for 21 days. It was hypothesized that children receiving the higher therapy dosage would have greater and more clinically significant benefits from ACQUIREc Therapy but that both groups of children would benefit from the therapy services.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Hemiparetic Cerebral Palsy

Interventions

Therapy services (ACQUIREc Therapy)OTHER

Dosage levels that are associated with the efficacy of intensive therapeutic services provided by OT and PT professionals.

Eligibility

Sex: ALLMin age: 3 YearsMax age: 8 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Children 3-6 years of age * Hemiparetic CP Exclusion Criteria: * No prior CI therapy treatments * No Botox for 6-months

Locations (1)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.